0000905148-24-000061.txt : 20240103
0000905148-24-000061.hdr.sgml : 20240103
20240103192523
ACCESSION NUMBER: 0000905148-24-000061
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240101
FILED AS OF DATE: 20240103
DATE AS OF CHANGE: 20240103
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Reinhart Harald
CENTRAL INDEX KEY: 0001835824
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38205
FILM NUMBER: 24509167
MAIL ADDRESS:
STREET 1: 4560 JINKE ROAD, BLDG. 1, FOURTH FLOOR
STREET 2: PUDONG
CITY: SHANGHAI
STATE: F4
ZIP: 201210
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Zai Lab Ltd
CENTRAL INDEX KEY: 0001704292
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
STATE OF INCORPORATION: E9
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4560 JINKE ROAD
STREET 2: BLDG. 1, 4F, PUDONG
CITY: SHANGHAI
STATE: F4
ZIP: 201210
BUSINESS PHONE: 862161632588
MAIL ADDRESS:
STREET 1: 4560 JINKE ROAD
STREET 2: BLDG. 1, 4F, PUDONG
CITY: SHANGHAI
STATE: F4
ZIP: 201210
4
1
form4.xml
X0508
4
2024-01-01
0001704292
Zai Lab Ltd
ZLAB
0001835824
Reinhart Harald
C/O ZAI LAB LIMITED
314 MAIN STREET, 4TH FLOOR, SUITE 100
CAMBRIDGE
MA
02142
true
See Remarks
false
American Depositary Shares
2024-01-01
4
M
0
17548
A
50863
D
American Depositary Shares
2024-01-03
4
S
0
4803
26.122
D
46060
D
Performance-Based Share Units
2024-01-01
4
A
0
17548
0
A
American Depositary Shares
17548
17548
D
Performance-Based Share Units
2024-01-01
4
M
0
17548
0
D
American Depositary Shares
17548
0
D
Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.
ADSs acquired on vesting of performance-based share units (PSUs). Each ADS represents ten Ordinary Shares of the issuer.
Each PSU represents a contingent right to receive one ADS, which represents ten Ordinary Shares of the issuer.
These ADSs were sold automatically to cover taxes upon vesting of PSUs.
The reporting person was granted PSUs on December 1, 2021 that vest based on the satisfaction of specified performance criteria between December 1, 2021 and December 31, 2025. On January 1, 2024, the performance-based vesting conditions were confirmed for PSUs representing 17,548 ADSs.
President and Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases
/s/ Bruce Blefeld, Attorney-in-Fact
2024-01-03